Burkehill Global Management’s Bicara Therapeutics BCAX Stock Holding History

Burkehill Global Management’s Portfolio BCAX Stock Details BCAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.99M	Buy	+100,000	New	+$1.72M	0.1%	123

Other funds holding BCAX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RTM

Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Burkehill Global Management's BCAX Position: Q1 2026 in Review

Burkehill Global Management opened a new position in Bicara Therapeutics (BCAX) in Q1 2026: 100,000 shares worth $1.99M. The stake represents 0.1% of the portfolio and ranks #123 among its holdings.

146 funds tracked by Wall St. Rank hold BCAX as of Q1 2026.

Burkehill Global Management held 100,000 shares of Bicara Therapeutics worth $1.99M as of Q1 2026.
Bicara Therapeutics was a new Burkehill Global Management position in Q1 2026.
Bicara Therapeutics made up 0.1% of Burkehill Global Management's portfolio in Q1 2026, its #123 holding.
146 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q1 2026.

Based on Burkehill Global Management's 13F filing for Q1 2026, filed 15 May 2026.